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Abstract
Between 2009 and 2013, polymerase-chain-reaction assay was
used to detect Treponema pallidum in the blood
samples collected from 296 patients with early syphilis (241
being HIV infected) and 102 patients (34.5%) had spirochetemia.
The presence of spirochetemia was associated with lower CD4
counts (per 10-cell/mm3 decrease, adjusted odds ratio (AOR),
1.020; 95% CI, 1.006–1.036) and secondary syphilis (AOR,
4.967; 95% CI, 2.016–12.238). Patients with early latent
syphilis were less likely to achieve serological response com-
pared with those with primary or secondary syphilis (AOR,
0.317; 95% CI, 0.142–0.708). However, serological response was
not affected by presence of spirochetemia or antibiotic
regimens.
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Laboratory diagnosis of syphilis is usually made by detection of
Treponema pallidum using dark-ﬁeld microscopy or serological
tests [1]. Recently, a polymerase-chain-reaction (PCR) assay
was developed to detect T. pallidum from clinical specimens
and to facilitate investigation of molecular epidemiology and
detection of macrolide resistance mutations [2–6]. In this
prospective observational study, we aimed to investigate the
prevalence of spirochetemia with the use of PCR assays among
patients with early syphilis, to identify the factors associated
with spirochetemia, and to evaluate the serological response
to antibiotic therapy among HIV-infected patients.
From September 2009 to July 2013, patients who presented
with untreated early syphilis (primary, secondary and early
latent syphilis) at the National Taiwan University Hospital
were enrolled. Information was collected on the demograph-
ics, stage of syphilis and sexual orientation, combination
antiretroviral therapy, and latest CD4 count and plasma HIV
RNA load when syphilis was diagnosed. All of the patients
without HIV infection (n = 55) were identiﬁed from the
anonymous voluntary counselling and testing (VCT) service for
HIV at this hospital.
The serological response of syphilis to antibiotics was
deﬁned as a ≧4-fold decline of rapid plasma reagin (RPR) titre
6 months after treatment. The analysis of serological response
was carried out using the last-observed-carried-forward
principle. Patients not infected with HIV were not included
in the assessment of treatment response because they were
followed at the VCT service after treatment.
Serum and plasma samples were collected using anticoag-
ulant-free and EDTA-coated containers (BD Vacutainer tubes,
Becton Dickinson, Plymouth, UK), respectively. Samples were
immediately transported to the laboratory and stored at
80°C. Treponemal DNA was extracted using the QIAamp
DNA mini Kit (Qiagen, Gmbh, Hildens, Germany) according to
the manufacturer’s protocol. The presence of T. pallidum was
determined by the ampliﬁcation of the pol Ι gene as described
previously [4]. The detection of macrolide resistance muta-
tions (A2058G or A2059G) in the 23S rRNA gene was
performed using PCR-restriction fragment length polymor-
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phism [5,7]. Molecular typing was performed based on three
treponemal genes: the number of 60-bp repeats in the acidic
repeat protein (arp) gene; the PCR-RFLP patterns of T. palli-
dum repeat (tpr) genes; and the sequence of a short region
(131–215 bp) in the tp0548 gene [8,9].
All statistical analyses were performed using SPSS software,
version 16.0 (SPSS Inc., Chicago, IL, USA). Categorical data
were analysed using one-way ANOVA, and continuous
variables were compared using Student’s t-test or the Mann–
Whitney U-test. Multiple logistic regression analysis was
performed to assess the factors associated with spirochetemia
and serological response. Results with a p value of <0.05 were
considered to be statistically signiﬁcant.
During the 4-year study period, 52 patients with primary
syphilis only, 159 with secondary syphilis and 85 with early
latent syphilis who had blood samples collected for PCR assays
were enrolled (Figure S1). The clinical characteristics of the
patients are shown in Table 1. Treponemal DNA was detected
in 102 patients (34.5%) (Table 1). Patients with secondary
syphilis (50.3%) had a higher rate of spirochetemia due to
T. pallidum than those with primary (21.2%) and early latent
syphilis (12.9%) (p < 0.001); 14f/f was the predominant strain
(seven out of 23 isolates) and was only identiﬁed in patients
with secondary syphilis (Table 1). Only one of 95 non-dupli-
cated samples (1.05%) tested positive for the 23S rRNA gene
of T. pallidum harbouring the macrolide resistance mutation
(A2058G).
In the multivariable model, patients with lower CD4 counts
(adjusted odds ratio (AOR), per 10-cell/mm3 decrease, 1.020;
95% conﬁdence interval (CI), 1.006–1.036) and secondary
syphilis (AOR, 4.967; 95% CI, 2.016–12.238) were associated
with the presence of spirochetemia (Table 2).
Of the 241 HIV-infected patients, 174 had completed
6 months of follow-up after treatment of syphilis. The only
factor associated with treatment outcome was syphilis stage.
Compared with those with primary or secondary syphilis,
patients with early latent syphilis were less likely to achieve
serological response (AOR, 0.317; 95% CI, 0.142–0.708)
(Table S2). The overall response rate was not affected by
the presence of spirochetemia (AOR, 1.877; 95% CI, 0.794–
4.439) (Table S2).
Discussion
We found that patients with secondary syphilis had a
signiﬁcantly higher rate of spirochetemia than those with
primary and early latent syphilis, and, in patients with HIV
infection, a lower CD4 count was associated with an increased
rate of spirochetemia. Furthermore, treatment response was
only affected by the syphilis stage but not by the presence of
spirochetemia or different antibiotics administered.
TABLE 1. Clinical characteristics of 296 patients with early syphilis
Variable
Patients with primary
syphilis only
Patients with
secondary syphilis
Patients with early
latent syphilis p-value
Patient number, n 52 159 85
Age, mean (SD), years 32.6 (8.7) 29.6 (6.9) 33.9 (6.3) <0.001
Male gender, n (%) 52 (100.0) 159 (100) 84 (98.8) 0.288
MSM, n (%) 52 (100.0) 154 (97.5) 81 (95.3) 0.253
RPR titre, median (range), log2 6.5 (2–10) 6 (2–10) 6 (2–10) 0.126
T. pallidum PCR (+) blood samples, n (%) 11 (21.2) 80 (50.3) 11 (12.9) <0.001
Macrolide resistance mutation (A2058G or A2059G),
n (% of ampliﬁable 23S rRNA)
0 1 (1.3) 0 0.880
Samples with full typing, n (% of PCR-positive blood samples) 2 (7.7) 19 (17.3) 2 (7.1) 0.231
14 f/f genotype, n (% of typeable samples) 0 7 (36.8) 0 0.347
HIV infection, n (%) 43 (82.7) 118 (74.2) 80 (94.1) 0.007
On cART in HIV-infected patients, n (%) 34 (79.1) 75 (63.6) 67 (83.8) 0.004
CD4 count in HIV-infected patients, mean (SD), cells/mm3 (n = 239)
>500 cells/mm3, n (%)
497.7 (226.6)
20 (46.5)
506.7 (241.9)
59 (50.9)
534.7 (281.7)
40 (50.0)
0.668
0.673
Plasma HIV RNA load, mean (SD), log10 copies/mL (n = 238) 2.49 (1.45) 2.92 (1.55) 2.21 (1.31) 0.004
Antibiotic treatment, n (%)
1-dose benzathine penicillin 16 (30.8) 64 (40.3) 20 (23.5)
3-dose benzathine penicillin 6 (11.5) 31 (19.5) 7 (8.3)
Azithromycin 30 (57.7) 62 (39.0) 58 (68.2)
Doxycycline 0 2 (1.3) 0
cART, combination antiretroviral therapy; MSM, men who have sex with men; PCR, polymerase-chain-reaction; RPR, rapid plasma reagin; SD, standard deviation.
TABLE 2. Multivariable analysis for factors associated with
positive PCR results for Treponema pallidum in patients with
early syphilis
Odds ratio 95% CI p-value
Age 0.983 0.939–1.029 0.457
Baseline RPR, per 1-log2 increase 1.184 0.967–1.437 0.087
Secondary vs. primary syphilis 4.967 2.016–12.238 <0.001
Early latent vs. primary syphilis 0.762 0.273–2.126 0.603
CD4 count (10-cell/mm3 decrease) 1.020 1.006–1.036 0.006
Plasma HIV RNA load, log10 0.824 0.594–1.142 0.245
CART 1.005 0.362–2.787 0.992
CART, combination antiretroviral therapy; RPR, rapid plasma reagin.
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Previous studies suggested that secondary and tertiary
syphilis are manifestations of immune reactions that fail to
clear the organism, due to a lack of activation of macrophages
by CD4 lymphocytes [10–12]. In our study, a lower CD4
count is associated with a higher rate of spirochetemia,
suggesting that progressive impaired immunity from HIV
infection may increase the likelihood of failing to clear
T. pallidum. The ﬁnding that HIV infection was not associated
with spirochetemia may be attributable to the fact that half of
our patients had CD4 counts >500 cells/mm3 and nearly 70%
were receiving combination antiretroviral therapy.
In previous studies [13,14], the serological response
decreased in the order of syphilis stage. Compared with early
latent syphilis in our study, patients with primary or secondary
syphilis had better serological response (p 0.005); however,
the response rate for patients with secondary and those with
primary syphilis was similar (p 0.956) (Table S2). While the
serological response rate to antibiotic therapy was higher in
patients with spirochetemia than in those without spirochet-
emia (84.1% vs. 69.4%, p 0.151), the difference was not
statistically signiﬁcant, which is likely to be due to small case
numbers in our study.
There are several limitations of our study. First, we only
collected blood samples from patients with early syphilis, which
precluded us from investigating the rate of spirochetemia in
patients with other stages of syphilis. Second, due to the
difﬁculty in follow-up, patients not infected with HIV were
excluded from the evaluation of serological response, which
may lead to underestimation of the effectiveness of the
antibiotics examined. Third, clinical criteria, instead of dark-
ﬁeld microscopy, were used to deﬁne syphilis. Subtle or
atypical dermatological or mucosal lesions of syphilis may be
misclassiﬁed.
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